Loading patent…
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsRosa Krajmalnik-Brown, Dae-Wook Kang, Jin Gyoon Park, Joshua Labaer, Zehra IIhan
Estimating the term…
The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteriodes and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.
-27. (canceled)
A method of increasing balance of a microbiome of a gut of a human subject having autism spectrum disorder (ASD) comprising:
A method of a selecting a subject for treating an autism spectrum disorder (ASD) or ASD-gut related symptoms/complications, comprising:
The method of claim 46, wherein the protein assay includes at least one of 2-Dimensional Gel Electrophoresis, 2-Dimensional Difference Gel Electrophoresis (2D-DIGE), MALDI TOF-MS, (2D-) LC-ESI-MS/MS, AQUA, and iTRAQ.
A method of a selecting a subject for treating an autism spectrum disorder (ASD) or ASD-gut related symptoms/complications, comprising:
Dependencies are inferred from the claim text.